- Home
- SBFG vs ARMP Comparison
SBFG vs ARMP Comparison
Compare SBFG & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | ARMP |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.8M | 156.4M |
| IPO Year | 2014 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SBFG | ARMP |
|---|---|---|
| Price | $27.55 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 11.4K | ★ 100.2K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 27.33 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.16 | $2.40 |
| 52 Week High | $28.38 | $14.98 |
Technical Indicators
Market Signals| Indicator | SBFG | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 51.47 |
| Support Level | $20.94 | $3.98 |
| Resistance Level | $28.38 | $5.60 |
| Average True Range (ATR) | 0.79 | 0.54 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 65.76 | 65.80 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.